宁波戴维医疗器械股份有限公司的主营业务是儿产科保育设备、微创外科手术器械以及急救手术ICU产 品。公司的主要产品是婴儿培养箱、婴儿辐射保暖台、新生儿黄疸治疗设备、黄疸检测设备、脑电监测 仪、亚低温治疗仪、经皮黄疸仪、婴儿T组合复苏器、医用空氧混合器、医用电动吸引器、新生儿专用 监护仪、医用加热仪、医用婴儿床、电动腔镜吻合器、手动腔镜吻合器、开放系列吻合器。目前，公司 被国家工信部认定为"制造业单项冠军培育企业"，同时荣获"浙江省知名商号"、"浙江省信用管理示范 企业"、"资信等级AAA级企业"、"浙江省'专精特新'中小企业"、"宁波市'专精特新'中小企业"等多项荣 誉称号。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 截至2025年一季报，共有2家机构持仓戴维医疗，其中QFII1家、保险1家，合计持股数125.29万股，持 股市值0.15亿元。 7月4日，戴维医疗今日收盘12.77元，下跌1.01%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到88.15倍，总市值36.78亿元。 ...

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均50.61倍，行业中值37.15倍，戴维医疗排 名第105位。 资金流向方面，6月30日，戴维医疗主力资金净流出670.26万元，近5日总体呈流出状态，5日共流出 158.70万元。 宁波戴维医疗器械股份有限公司的主营业务是儿产科保育设备、微创外科手术器械以及急救手术ICU产 品。公司的主要产品是婴儿培养箱、婴儿辐射保暖台、新生儿黄疸治疗设备、黄疸检测设备、脑电监测 仪、亚低温治疗仪、经皮黄疸仪、婴儿T组合复苏器、医用空氧混合器、医用电动吸引器、新生儿专用 监护仪、医用加热仪、医用婴儿床、电动腔镜吻合器、手动腔镜吻合器、开放系列吻合器。目前，公司 被国家工信部认定为"制造业单项冠军培育企业"，同时荣获"浙江省知名商号"、"浙江省信用管理示范 企业"、"资信等级AAA级企业"、"浙江省'专精特新'中小企业"、"宁波市'专精特新'中小企业"等多项荣 誉称号。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总 ...

最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗87.1163.473.0536.35亿行业平均 50.9748.964.68108.42亿行业中值36.6736.602.4749.87亿1天益医疗-1782.30-3052.891.9022.71亿2澳华内 镜-692.58347.365.5572.99亿3诺唯赞-414.64-490.412.2788.73亿4爱朋医疗-382.20290.364.6031.36亿5博晖 创新-331.28525.693.5448.61亿6奥精医疗-149.94-219.761.9827.83亿7硕世生物-138.80-2028.201.2440.60亿 8睿昂基因-101.98-83.721.4513.20亿9康泰医学-86.93-73.453.1057.22亿10中红医疗-72.23-57.610.9150.19亿 11热景生物-59.61-68.684.40131.18亿 来源：金融界 6月 ...

Core Viewpoint - David Medical's stock closed at 12.4 yuan, down 2.52%, with a rolling PE ratio of 85.59 times, and a total market value of 3.571 billion yuan [1] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, radiant warmers, jaundice treatment devices, EEG monitors, and more [1] - As of Q1 2025, two institutions held shares in David Medical, with a total of 1.2529 million shares valued at 0.015 billion yuan [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1] Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing David Medical at 102nd in the industry ranking [2] - The company's Q1 2025 performance showed a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78%, with a gross margin of 57.13% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in revenue and profit while maintaining a high PE ratio compared to industry averages [1][2] - As of May 7, David Medical's stock closed at 12.16 yuan, with a PE ratio of 83.93, which is significantly higher than the industry average of 49.02 and the median of 36.25 [1][2] - The company has a total market capitalization of 3.502 billion yuan, ranking 101st in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported a revenue of 121 million yuan, representing a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% from the previous year [2] - The company's gross profit margin stands at 57.13%, indicating a relatively strong profitability despite the decline in revenue and net profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]